Central nervous system progression in advanced non–small cell lung cancer patients with EGFR mutations in response to first-line treatment with two EGFR-TKIs, gefitinib and erlotinib: a comparative study

Lignende værker

• Shikonin sensitizes wild-type EGFR NSCLC cells to erlotinib and gefitinib therapy
  af: Li, Yang-Ling, et al.
  Udgivet: (2018)
• Combined treatment with metformin and gefitinib overcomes primary resistance to EGFR-TKIs with EGFR mutation via targeting IGF-1R signaling pathway
  af: Pan, Yong-hong, et al.
  Udgivet: (2018)
• Microwave ablation combined with EGFR-TKIs versus only EGFR-TKIs in advanced NSCLC patients with EGFR-sensitive mutations
  af: Wei, Zhigang, et al.
  Udgivet: (2017)
• Systems assessment of intercalated combination of chemotherapy and EGFR TKIs versus chemotherapy or EGFR TKIs alone in advanced NSCLC patients
  af: Yan, Han, et al.
  Udgivet: (2015)
• Estimation of cell-free circulating EGFR mutation concentration predicts outcomes in NSCLC patients treated with EGFR-TKIs
  af: Zhu, Yan-juan, et al.
  Udgivet: (2017)